Question 1

What are the potential side effects of silmitasertib and the chemotherapy drugs used in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors clinical trial (NCT06541262). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options I have?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors clinical trial (NCT06541262). Contact the study team or your healthcare provider for specific answers.

Question 3

What tests will be done to monitor my progress during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors clinical trial (NCT06541262). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic for treatment and assessments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors clinical trial (NCT06541262). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects or complications during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors clinical trial (NCT06541262). Contact the study team or your healthcare provider for specific answers.

Question 6

Is there a chance that I could receive a placebo or not receive the new treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors clinical trial (NCT06541262). Contact the study team or your healthcare provider for specific answers.

What this study is about